| 106 | 0 | 50 |
| 下载次数 | 被引频次 | 阅读次数 |
结直肠癌（CRC）是全球高发的消化系统恶性肿瘤，其晚期患者的复发转移及化疗耐药仍是制约临床疗效的重要挑战。近年来，具有高安全性和多维药理活性的天然多酚化合物姜黄素在抗CRC研究中受到关注。研究发现，姜黄素抗CRC具有“多靶点、多机制”协同调控的特性，既可通过诱导多重程序性细胞死亡、阻滞细胞周期及抑制上皮-间充质转化等抑制肿瘤生长和转移，又可调节肠道菌群以重塑肿瘤微环境，还可逆转化疗耐药性等发挥抗CRC作用。因此，姜黄素有望成为CRC综合治疗方案中有价值的辅助药物。未来需依托精准递送技术的优化及高质量临床试验的进一步验证，推动姜黄素向临床应用的实质性转化。
Abstract：Colorectal cancer(CRC) is one of the most prevalent malignant tumors of the digestive system world‑wide.In patients with advanced CRC, recurrence, metastasis, and chemoresistance remain major challenges that limit clinical efficacy.In recent years, curcumin, a natural polyphenolic compound characterized by high safety and diverse pharmacological activities, has attracted increasing attention in anti-CRC research.Evidence suggests that curcumin ex‑erts anti-CRC effects through a “multi-target, multi-mechanism” synergistic regulatory profile.It can inhibit tumor growth and metastasis by inducing multiple forms of programmed cell death, causing cell cycle arrest, and suppressing epithelial-mesenchymal transition(EMT).In addition, curcumin modulates the gut microbiota and improves the tumor microenvironment through microbiota remodeling, and it can also reverse chemoresistance in CRC.Therefore, curcumin is considered a promising adjuvant agent in comprehensive CRC treatment strategies.Future work should focus on opti‑mizing precision delivery systems and conducting high-quality clinical trials to facilitate its effective translation into clini‑cal application.
[1]SIEGEL R L, WAGLE N S, CERCEK A, et al. Colorectal can‑cer statistics, 2023[J]. CA Cancer J Clin, 2023,73(3):233-254.
[2]MUHAMMAD N, USMANI D, TARIQUE M, et al. The role of natural products and their multitargeted approach to treat solid cancer[J]. Cells, 2022,11(14):2209.
[3]GHORBANI-NEJAD B, BAGHANI M, AMIRI S, et al. Curcum‑in:multifaceted biological actions and therapeutic implications:a narrative review[J]. Inflammopharmacology, 2025,33(11):6309-6327.
[4]ZHOU H L, ZHUANG Y P, LIANG Y W, et al. Curcumin ex‑erts anti-tumor activity in colorectal cancer via gut microbiota-me‑diated CD8+T cell tumor infiltration and ferroptosis[J]. Food&Function, 2025,16(9):3671-3693.
[5]BROCKMUELLER A, RUIZ DE PORRAS V, SHAKIBAEI M.Curcumin and its anti-colorectal cancer potential:from mecha‑nisms of action to autophagy[J]. Phytother Res, 2024,38(7):3525-3551.
[6]YUAN Z L, HU J, CAI C F, et al. Integrated network pharmacol‑ogy and experimental verification to reveal the mechanisms of cur‑cumin in the treatment of colorectal cancer[J]. Front Pharmacol,2026,16:1703562.
[7]CAO J F, HANG K, ZHANG H, et al. Cuproptosis induced by curcumin interfering with proliferation and energy metabolism in colorectal cancer:3D tumor model and computational simulations reveal curcumin inhibition of HSPD1 and CALCOCO2[J]. Eur J Pharmacol, 2025,1003:177964.
[8]SHADNOUSH M, MOMENAN M, SEIDEL V, et al. A compre‑hensive update on the potential of curcumin to enhance chemosen‑sitivity in colorectal cancer[J]. Pharmacol Rep, 2025,77(1):103-123.
[9]GUÉGUINOU M, IBRAHIM S, BOURGEAIS J, et al. Curcumin and NCLX inhibitors share anti-tumoral mechanisms in microsat‑ellite-instability-driven colorectal cancer[J]. Cell Mol Life Sci,2022,79(6):284.
[10]XU W, SHEN Y. Curcumin affects apoptosis of colorectal cancer cells through ATF6-mediated endoplasmic reticulum stress[J].Chem Biol Drug Des, 2024,103(1):e14433.
[11]PATNAIK R, VARGHESE R, AL-KABANI A, et al. Curcumin inhibits protease activated receptor 2-induced ERK phosphoryla‑tion calcium mobilization and anti-apoptotic signaling in inflam‑mation-driven colorectal cancer cells[J]. Cells, 2025,14(18):1451.
[12]MA T F, FAN Y R, ZHAO Y H, et al. Emerging role of autopha‑gy in colorectal cancer:progress and prospects for clinical inter‑vention[J]. World J Gastrointest Oncol, 2023,15(6):979-987.
[13]WANG Y, LIU M, JIA X, et al. AMPK/mTOR/ULK1 pathway participates in autophagy induction by curcumin in colorectal ade‑noma mouse model[J]. Drug Dev Res, 2025,86(5):e70115.
[14]SIPOS F, MUZES G. Interconnection of CD133 stem cell marker with autophagy and apoptosis in colorectal cancer[J]. Int J Mol Sci, 2024,25(20):11201.
[15]CHEN M, TAN A H, LI J. Curcumin represses colorectal cancer cell proliferation by triggering ferroptosis via PI3K/AKT/mTOR signaling[J]. Nutr Cancer, 2023,75(2):726-733.
[16]MING T Q, LEI J R, PENG Y H, et al. Curcumin suppresses colorectal cancer by induction of ferroptosis via regulation of p53and solute carrier family 7 member 11/glutathione/glutathione peroxidase 4 signaling axis[J]. Phytother Res, 2024,38(8):3954-3972.
[17]XIN W, ZHANG Y. Curcumin activates the JNK signaling path‑way to promote ferroptosis in colon cancer cells[J]. Chem Biol Drug Des, 2024,103(3):e14468.
[18]LI P H, PU S M, LIN C, et al. Curcumin selectively induces co‑lon cancer cell apoptosis and S cell cycle arrest by regulates Rb/E2F/p53 pathway[J]. J Mol Struct, 2022,1263:133180.
[19]YANG Z, ZHAO R, GAO W J. The effects of curcumin on the bi‑ological behavior of colorectal cancer cells through the JAK/STAT3 and RAS/MAPK/NF-κB pathways[J]. Invest Clin, 2022,63(4):353-362.
[20]LI Q, DING Y T, OU Y, et al. Curcuminoids modulated the IL-6/JAK/STAT3 signaling pathway in LoVo and HT-29 colorectal cancer cells[J]. Curr Pharm Des, 2023,29(36):2867-2876.
[21]SABIR D K. Targeting the Hippo and Rap1 signaling pathways:the anti-proliferative effects of curcumin in colorectal cancer cell lines[J]. Med Oncol, 2025,42(2):41.
[22]KIM H K, LEE R A, HONG K S, et al. Cancer-specific cytotox‑icity of curcumin through regulation of integrin β1 expression in colon cancer[J]. Sci Rep, 2025,15(1):39218.
[23]WENG W H, GOEL A. Curcumin and colorectal cancer:an up‑date and current perspective on this natural medicine[J]. Semin Cancer Biol, 2022,80:73-86.
[24]LU Y, ZHANG R Z, ZHANG X J, et al. Curcumin may reverse5-fluorouracil resistance on colonic cancer cells by regulating TET1-NKD-Wnt signal pathway to inhibit the EMT progress[J].Biomed Pharmacother, 2020,129:110381.
[25]LIU F, ZHU C M, MA H, et al. Curcumin targets miR-134-5p to suppress the progression of colorectal cancer through regulating the CDCA3/CDK1 pathway[J]. Naunyn Schmiedebergs Arch Pharmacol, 2024,397(1):109-122.
[26]LIU C F, ROKAVEC M, HUANG Z K, et al. Curcumin acti‑vates a ROS/KEAP1/NRF2/miR-34a/b/c cascade to suppress colorectal cancer metastasis[J]. Cell Death Differ, 2023,30(7):1771-1785.
[27]WANG X L, CHAI R D, LI J Y, et al. Curcumin protects extra‑cellular matrix to maintain microenvironmental stability inhibiting colon cancer metastasis through HPSE/IL-6/STAT5 axis[J].Naturwissenschaften, 2025,112(4):47.
[28]GE S K, SUN X, SANG L M, et al. Curcumin inhibits malignant behavior of colorectal cancer cells by regulating M2 polarization of tumor-associated macrophages and metastasis associated in colon cancer 1(MACC1)expression[J]. Chem Biol Drug Des, 2023,102(5):1202-1212.
[29]DENG W X, XIONG X J, LU M Y, et al. Curcumin suppresses colorectal tumorigenesis through restoring the gut microbiota and metabolites[J]. BMC Cancer, 2024,24(1):1141.
[30]GUO X X, XU Y, GENG R X, et al. Curcumin alleviates dex‑tran sulfate sodium-induced colitis in mice through regulating gut microbiota[J]. Mol Nutr Food Res, 2022,66(8):2100943.
[31]ELBADAWY M, HAYASHI K, AYAME H, et al. Anti-cancer activity of amorphous curcumin preparation in patient-derived colorectal cancer organoids[J]. Biomed Pharmacother, 2021,142:112043.
[32]ZHANG N, GAO M, WANG Z H, et al. Curcumin reverses doxorubicin resistance in colon cancer cells at the metabolic level[J]. J Pharm Biomed Anal, 2021,201:114129.
[33]FAN W H, WANG F C, JIN Z, et al. Curcumin synergizes with cisplatin to inhibit colon cancer through targeting the microRNA-137-glutaminase axis[J]. Curr Med Sci, 2022,42(1):108-117.
[34]HAN W, YIN H L, MA H, et al. Curcumin regulates ERCC1 ex‑pression and enhances oxaliplatin sensitivity in resistant colorec‑tal cancer cells through its effects on miR-409-3p[J]. Evid Based Complement Alternat Med, 2020,2020:8394574.
[35]LI G L, FANG S N, SHAO X, et al. Curcumin reverses NNMTinduced 5-fluorouracil resistance via increasing ROS and cell cy‑cle arrest in colorectal cancer cells[J]. Biomolecules, 2021,11(9):1295.
[36]ZHENG Z H, YOU H Y, FENG Y J, et al. LncRNA KC‑NQ1OT1 is a key factor in the reversal effect of curcumin on cispl‑atin resistance in the colorectal cancer cells[J]. Mol Cell Bio‑chem, 2021,476(7):2575-2585.
基本信息:
中图分类号:R285
引用信息:
[1]宁新迈,张俐佳,刘松江.姜黄素抗结直肠癌的分子机制研究进展[J].山东医药,2026,66(07):149-154.
基金信息:
黑龙江省省属本科高校中央支持地方高校改革发展资金项目（2020GSP07）; 黑龙江省中医药科研项目（GY2022-05）; 黑龙江省中医药管理局省级名中医专家传承工作室建设项目
2026-07-16
2026-07-16
2026-07-16